Clinical trial
A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480)…
NCT03061201 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT03061201 |
|---|---|
| Title | A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A |
| Official title | A PHASE 1/2, OPEN-LABEL, ADAPTIVE, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF SB-525 (PF-07055480) (RECOMBINANT AAV2/6 HUMAN FACTOR 8 GENE THERAPY) IN ADULT SUBJECTS WITH SEVERE HEMOPHILIA A |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Biological |
| Interventions | SB-525 (PF-07055480) |
| Enrollment | 13 |
| Start date | Jun 21, 2017 |
| Primary completion | Jul 16, 2024 |
| Completion | Jul 16, 2024 |
| First posted | Feb 23, 2017 |
| Last update posted | Sep 30, 2025 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: